首页> 外文期刊>Journal of Medicinal Chemistry >Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo2,3-dpyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)
【24h】

Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo2,3-dpyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)

机译:研究3-((3R,4R)-4-甲基-3-(甲基(7H-吡咯并2,3-d嘧啶-4-基)氨基)哌啶-1-基)-3-氧代丙腈(CP-690,550)的手性、构象和选择性激酶抑制作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.
机译:在这里,我们研究了立体化学在临床相关的 Janus 激酶 3 (Jak3) 抑制剂 1 (CP-690,550) 中发挥的重要作用。对药物的所有四种对映体立体异构体进行了合成,对每种化合物的检查显示,只有对映纯3R,4R异构体能够阻断Stat5磷酸化(Jak3依赖性)。在超过350种激酶的panel中对每种化合物进行了分析,结果显示Jak家族激酶对这些相关化合物具有高水平的选择性。每种立体异构体都保留了与 Jak3 和 Jak2 的一定程度的结合,并且进一步发现 3R、4S 和 3S、4R 立体异构体对激酶 STE7 和 STE20 亚家族的选定成员具有结合亲和力。最后,评估了每种立体异构体的最小能量构象和Jak3的分子对接,以更好地了解每种化合物的选择性和效力特征。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号